How Can a Patent Be Enforced in Canada in 2026: Courts, PM(NOC) Actions, Injunctions & Damages

Understanding how can a patent be enforced is the threshold question for every innovator, in-house counsel, and life-sciences company operating in Canada. The Canadian enforcement landscape in 2026 is shaped by a distinct division between the Federal Court (the primary patent litigation forum) and provincial courts, a specialised statutory pathway for pharmaceutical patents under the Patented Medicines (Notice of Compliance) Regulations, commonly known as the PM(NOC) regulations, and evolving Federal Court of Appeal jurisprudence on the availability of permanent injunctions. This guide provides a cradle-to-court roadmap covering forum selection, the PM(NOC) pharma pathway, patent injunction Canada requirements for both interlocutory and permanent relief, patent infringement damages Canada methodologies, and cross-border considerations for holders of foreign patents.

TL;DR, A Canadian patent is enforced by preserving evidence of infringement, issuing a demand letter, and commencing an action in the Federal Court of Canada (or, for medicines, a PM(NOC) proceeding). Remedies include injunctions, damages or an accounting of profits, and border measures.

Immediate steps for patent owners who suspect infringement:

• Preserve evidence. Collect and safeguard physical samples, web archives, purchase records, and technical analysis that document the infringing product or process before the infringer can alter or remove them.
• Send a demand letter. A well-crafted cease-and-desist letter puts the infringer on notice, may trigger an early resolution, and creates a litigation record that can later support claims for enhanced damages or wilful infringement.
• Engage experienced IP litigation counsel. Forum selection, evidence strategy, and remedy choice differ significantly between a standard Federal Court infringement action and a PM(NOC) proceeding, counsel should evaluate the optimal path before any filing.

How Can a Patent Be Enforced: Overview of Enforcement Pathways in Canada

Canada’s Patent Act (R.S.C., 1985, c. P-4) grants patent holders the exclusive right to make, construct, use, and sell the patented invention throughout the country. When that right is infringed, several enforcement pathways are available, and the right strategy depends on the technology, the infringer’s identity, and the urgency of the situation.

The principal routes are:

• Demand letter and negotiation. Many disputes resolve without litigation once the infringer receives a formal notice backed by a claim chart and evidence of infringement.
• Civil action in the Federal Court of Canada. This is the primary, and, for most patent owners, the preferred, litigation forum for statutory patent infringement claims.
• PM(NOC) proceedings. A statutory pathway under the PM(NOC) regulations designed specifically for pharmaceutical patent disputes arising when a generic or biosimilar manufacturer seeks regulatory approval.
• Provincial court proceedings. Available in limited circumstances, generally for related contractual or licensing claims rather than direct infringement.
• Border measures. Patent holders may request assistance from the Canada Border Services Agency (CBSA) under the Combating Counterfeit Products Act to detain goods suspected of infringing IP rights at the border.

Demand Letter and Pre-Litigation Options

A demand letter is frequently the first enforcement step. An effective letter identifies the patent at issue, describes the infringing conduct with particularity, attaches or references a claim chart mapping the patent claims to the accused product or process, and sets a deadline for a response. The letter should be carefully calibrated: it must be assertive enough to establish urgency yet avoid statements that could later be characterised as misuse or abuse of patent rights under the Competition Bureau’s IP enforcement guidelines.

Alternative Dispute Resolution and Licensing

Before committing to litigation, patentees should consider mediation, arbitration, or licensing negotiations. Licensing can monetise the patent without the cost and delay of a full trial. Canadian courts generally encourage ADR; the Federal Court’s case-management process often provides mediation windows early in proceedings. Where the infringer is a potential long-term business partner, a negotiated licence may preserve commercial relationships while securing fair compensation.

Forum Choice: How Can a Patent Be Enforced in Federal Court Versus Provincial Courts

Selecting the right forum is one of the most consequential strategic decisions in Canadian patent enforcement. The Federal Court of Canada is the dominant venue for patent infringement actions, but provincial courts retain a limited role in related disputes.

What the Federal Court Offers

The Federal Court has explicit statutory jurisdiction over patent infringement claims under Section 20 of the Federal Courts Act and the Patent Act. It is staffed by judges with deep IP expertise, and its procedural rules, particularly those governing document discovery, expert evidence, and claim construction, are tailored to the complexity of patent litigation. Key advantages include:

• Nationwide remedies. A Federal Court injunction operates across all Canadian provinces and territories, eliminating the fragmentation risk of province-by-province relief.
• Specialised case management. Patent cases are assigned early to a case-management judge who controls timelines, resolves procedural disputes, and can schedule expedited interlocutory hearings when urgent relief is needed.
• Comprehensive remedies. The Federal Court can grant injunctions (interlocutory and permanent), award damages or an accounting of profits, order delivery-up or destruction of infringing goods, and issue declarations of validity or infringement.
• Established PM(NOC) procedures. All PM(NOC) proceedings must be commenced in the Federal Court, and the court has developed extensive practice directions for these actions.

When Provincial Routes Are Relevant

Provincial superior courts may exercise jurisdiction where the patent dispute overlaps with contractual claims, for example, a licence agreement governed by provincial law, a breach of fiduciary duty by a former employee, or a trade-secret misappropriation claim that accompanies the patent infringement. Some litigants have attempted to bring patent infringement claims in provincial courts, but jurisprudence confirms that the Federal Court is the preferred and most efficient forum. The practical disadvantages of provincial proceedings for patent matters include the absence of nationwide remedies, a smaller pool of judges with patent experience, and the risk of parallel proceedings if the defendant counterclaims in Federal Court.

PM(NOC) Actions: Pharma-Specific Patent Enforcement Pathway

The PM(NOC) regulations create a unique enforcement mechanism that links pharmaceutical patent rights to the drug-approval process administered by Health Canada. For innovator pharmaceutical and biotech companies, understanding this pathway is essential because it determines whether a generic or biosimilar competitor can enter the market and, if so, on what timeline.

How the PM(NOC) Regime Works

When an innovator company obtains a patent covering a drug product or its use, it may list that patent on the Patent Register maintained by Health Canada. A subsequent applicant, typically a generic manufacturer filing an Abbreviated New Drug Submission (ANDS), must then either accept a delay in receiving its Notice of Compliance (NOC) until the listed patent expires, or serve an allegation on the innovator asserting that the patent is invalid or would not be infringed by the proposed generic product. Once the innovator receives this allegation, it may commence an action in the Federal Court within 45 days.

Filing that action triggers an automatic stay that prevents Health Canada from issuing the NOC to the generic manufacturer for a prescribed period.

PM(NOC) Timelines and Expedited Steps

Stay of NOC, Evidentiary Threshold, and Expert Evidence

The automatic stay under the PM(NOC) regulations is a powerful tool for innovators because it keeps the generic product off the market while litigation proceeds. However, the generic manufacturer may move to have the stay lifted if the innovator’s action is not being prosecuted diligently. The evidentiary burden on the innovator is substantial: the patentee must demonstrate, through detailed expert and factual evidence, that the generic product will infringe a valid patent claim. Expert evidence, often from scientists and clinicians with direct knowledge of the patented technology and the generic formulation, is central to these proceedings. Claim construction disputes are frequently determinative, and the Federal Court applies a purposive construction approach consistent with established Supreme Court of Canada jurisprudence.

Remedies Available After a PM(NOC) Decision

If the Federal Court finds in favour of the innovator, the generic manufacturer’s NOC will not issue until the patent expires, effectively keeping the generic off the market. If the court dismisses the action and the generic later enters the market, the innovator may still pursue a separate full action for infringement and damages. Conversely, a generic manufacturer that was wrongfully kept off the market by the stay may seek damages from the innovator under Section 8 of the PM(NOC) regulations. Industry observers expect the interaction between PM(NOC) outcomes and the PMPRB’s pricing framework to receive further judicial scrutiny as the 2026 Guidelines continue to influence patentee strategy.

Patent Injunction Canada Requirements: Interlocutory Versus Permanent Relief

Injunctive relief is often the most valuable remedy available to a patent holder, particularly in fast-moving technology and life-sciences markets where monetary damages alone cannot compensate for lost market position. Understanding patent injunction Canada requirements for both interlocutory and permanent orders is critical to enforcement strategy.

Interlocutory Injunctions

A patent holder seeking an interlocutory injunction, an order restraining the alleged infringer before trial, must satisfy the well-established three-part test derived from Supreme Court of Canada jurisprudence:

• Serious issue to be tried. The patentee must demonstrate that the infringement claim is not frivolous or vexatious. In most patent cases this threshold is met relatively easily, but a strong prima facie showing of both validity and infringement strengthens the motion considerably.
• Irreparable harm. The patentee must show that it will suffer harm that cannot be adequately compensated by damages. In pharmaceutical and biotechnology cases, irreparable harm frequently arises from price erosion, loss of market share to generic entrants, and the practical impossibility of restoring pre-infringement pricing once generics establish a presence.
• Balance of convenience. The court weighs the relative hardship to each party and the public interest. In life-sciences disputes, the public interest in access to affordable medicine may weigh against an interlocutory injunction, particularly where the patent’s validity is contested.

Permanent Injunctions and the 2024 Federal Court of Appeal Commentary

Following a finding of infringement at trial, the successful patentee will typically seek a permanent injunction. In late 2024, the Federal Court of Appeal addressed the framework for permanent injunctions in the patent context. The court’s commentary indicated that a successful patentee is presumptively entitled to a permanent injunction absent exceptional circumstances, such as overriding public-interest concerns or situations where the injunction would cause disproportionate harm relative to its benefit. Early indications suggest this approach has provided greater predictability for life-sciences patentees who prevail at trial, reinforcing the value of injunctive relief as the primary enforcement remedy. However, the court also acknowledged that circumstances may exist where damages are a more appropriate remedy, leaving room for fact-specific flexibility.

Evidence to Secure Interlocutory Injunctions

Practical evidence preparation is essential. Patentees should compile market-share data and pricing analyses demonstrating the commercial impact of the infringer’s entry, expert reports on the difficulty of quantifying damages (particularly in fragmented or rapidly evolving markets), and evidence that the infringer’s product is being marketed or is imminently ready for launch. Affidavits from corporate officers describing the business harm and from technical experts confirming infringement form the evidentiary backbone of any interlocutory motion. Delay in seeking relief will count against the applicant, courts expect prompt action once infringement is discovered.

Cross-Border Injunction Enforcement Considerations

A Federal Court injunction is enforceable throughout Canada, but it does not extend to other jurisdictions. Where an infringer manufactures abroad and imports into Canada, the injunction may be supplemented by border measures through the CBSA. Patentees with parallel patents in multiple countries should coordinate enforcement to prevent the infringer from shifting production or sales channels across borders.

Patent Infringement Damages Canada: Monetary Remedies and Quantification

Where injunctive relief is unavailable or insufficient, or as a complement to an injunction, patent holders may pursue monetary compensation. Canadian law provides two principal monetary remedies for patent infringement, compensatory damages and an accounting of profits, and the choice between them can significantly affect the quantum recovered.

Compensatory Damages

Compensatory damages aim to place the patentee in the position it would have occupied but for the infringement. The two dominant quantification approaches are:

• Lost profits. If the patentee can demonstrate that it would have made the sales captured by the infringer, it may recover its lost profits on those sales. This requires evidence of manufacturing capacity, market demand, and the absence of acceptable non-infringing alternatives. The patentee bears the burden of proving a causal link between the infringement and the lost sales.
• Reasonable royalty. Where lost profits cannot be proved, for instance, because the patentee does not manufacture or because the infringer’s product serves a different market segment, the court may award a reasonable royalty. This is calculated based on a hypothetical negotiation between a willing licensor and a willing licensee, taking into account the patent’s commercial value, comparable licence agreements, industry norms, and the profitability of the infringing activity.

Accounting of Profits

As an alternative to damages, the patentee may elect an accounting of the infringer’s profits. This remedy disgorges the profit attributable to the infringement, and it can be particularly advantageous where the infringer’s profits exceed the patentee’s lost profits, for example, if the infringer has lower production costs or superior market access. The court will apportion profits to determine how much is attributable to the patented feature versus other factors contributing to the infringer’s sales.

Proof, Experts, and Quantification

Quantifying patent infringement damages Canada cases require detailed economic evidence. Expert economists and industry specialists typically prepare damages models projecting lost sales, price erosion, and market-share displacement. In reasonable-royalty cases, the expert will construct the hypothetical negotiation, drawing on comparable licences, the Georgia-Pacific factors adapted to Canadian practice, and market data. Early engagement of damages experts, ideally before or shortly after commencing the action, ensures that the evidence is preserved and the quantification theory is robust. Courts have rejected speculative damages claims; the evidentiary foundation must be solid.

Limitation Periods and Mitigation

Patent infringement claims in Canada are generally subject to a six-year limitation period from the date the infringement occurred or was discovered. The patentee has a duty to mitigate its losses, for example, by continuing to market its product and not unreasonably withdrawing from the market. Failure to mitigate may reduce the damages award. Counsel should also consider whether pre-judgment interest and costs, which can be substantial in complex patent litigation, are available and should be claimed.

Cross-Border Enforcement: Can a U.S. Patent Be Enforced in Canada?

A frequently asked question is whether a U.S. patent can be enforced in Canada. The short answer is no, patent rights are strictly territorial. A United States patent grants rights only within U.S. territory and has no direct legal effect in Canada. To enforce patent rights in Canada, the patent holder must hold a granted Canadian patent covering the same invention.

For multinational patentees, this territorial principle creates both obligations and strategic opportunities:

• Obtain a Canadian counterpart. If you filed under the Patent Cooperation Treaty (PCT) or directly with the Canadian Intellectual Property Office (CIPO), ensure your Canadian application has been prosecuted to grant. A Canadian patent search through the CIPO database confirms the status of your Canadian rights.
• Coordinate parallel litigation. Where infringement occurs in both the United States and Canada, parallel proceedings can create litigation pressure and prevent the infringer from exploiting jurisdictional gaps. Discovery obtained in one jurisdiction may (subject to procedural constraints) inform strategy in the other.
• Border measures. Patent holders can request the CBSA’s assistance to detain goods suspected of infringing Canadian patent rights at the border, a particularly useful tool when infringing products are manufactured abroad.
• Recognition of foreign judgments. Canadian courts may recognise foreign judgments under comity principles, but this does not substitute for a Canadian patent. A U.S. court finding of infringement of a U.S. patent is not directly enforceable as a basis for Canadian patent infringement.

Practical Checklist for Cross-Border Patentees

Before commencing enforcement in Canada, cross-border patentees should confirm that their Canadian patent is in force and all maintenance fees are current; conduct a Canadian patent search to identify the infringing product on the Canadian market; assess whether the Canadian patent claims cover the specific product or process at issue (claim scope may differ from the U.S. counterpart); and determine whether parallel U.S. proceedings create any discovery or strategic synergies.

Practical Litigation Checklist and Enforcement Playbook

Effective patent enforcement requires meticulous preparation before any court filing. The following step-by-step checklist distils the key actions that patent holders should take when they suspect infringement in Canada:

1. Confirm patent status. Verify that the Canadian patent is granted, in force, and that all maintenance fees have been paid. Check the CIPO database for current status.
2. Preserve evidence. Purchase or otherwise obtain samples of the allegedly infringing product. Archive websites, marketing materials, product specifications, and regulatory filings. Consider engaging a forensic expert if the infringement involves a process.
3. Mark your products. Ensure that your own products and packaging bear the Canadian patent number. While marking is not mandatory for enforcement, it can support claims for damages and demonstrates diligence.
4. Prepare a claim chart. Map each element of the asserted patent claims to the features of the infringing product or process. This chart will form the core of both the demand letter and the eventual statement of claim.
5. Send a demand letter. Issue a clear, well-documented cease-and-desist letter giving the infringer a reasonable deadline to respond.
6. Select the forum. In most cases, the Federal Court is the appropriate venue. If the dispute involves a pharmaceutical patent listed on the Patent Register, the PM(NOC) pathway may apply.
7. Engage experts early. Retain technical experts (for infringement and validity analysis) and economic experts (for damages quantification) before filing. Early expert engagement strengthens both the pleadings and any interlocutory motion.
8. Plan for interim relief. If the infringer’s market entry is imminent, prepare an interlocutory injunction motion simultaneously with the statement of claim.
9. Develop a damages model. Begin constructing the damages theory, lost profits, reasonable royalty, or accounting of profits, as early as possible, and ensure that the supporting data is being collected and preserved.

Sample Timelines and Cost Expectations

Patent enforcement timelines in Canada vary considerably depending on the complexity of the technology, the forum, and the parties’ conduct. The following high-level timelines provide a general orientation for planning purposes.

Costs in Canadian patent litigation are substantial. A full Federal Court infringement action through trial may involve legal fees ranging from several hundred thousand to several million Canadian dollars, depending on the complexity and number of patents at issue. PM(NOC) proceedings are generally less expensive than full actions because of the expedited timeline and narrower scope, but they still require significant investment in expert evidence and legal preparation. Patentees should budget for expert fees, discovery costs, and potential adverse cost awards if unsuccessful.

Conclusion: Enforcing Patents in Canada Requires Strategic Precision

Understanding how can a patent be enforced in Canada demands more than a textbook knowledge of the Patent Act. It requires a strategic assessment of forum selection (Federal Court versus provincial courts), a command of the PM(NOC) regulations for life-sciences patentees, familiarity with evolving injunction standards, and the ability to build a robust damages case. The 2026 landscape, shaped by the PMPRB’s pricing framework and the Federal Court of Appeal’s recent guidance on permanent injunctions, rewards patentees who prepare meticulously, engage experts early, and act with urgency when infringement is detected.

Patent enforcement in Canada is a complex, multi-step process, but with the right preparation and experienced IP litigation counsel, patentees can protect their innovations effectively. Whether the dispute involves a pharmaceutical blockbuster subject to PM(NOC) proceedings or a technology product entering the Canadian market, the enforcement tools available through the Federal Court are powerful, provided they are wielded with precision.

This article provides general information about patent enforcement in Canada and does not constitute legal advice. Readers should consult qualified IP litigation counsel for guidance specific to their circumstances.

Last reviewed: 22 May 2026

Sources

1. Justice Laws Website, Patented Medicines (Notice of Compliance) Regulations
2. Justice Laws Website, Patent Act (R.S.C., 1985, c. P-4)
3. Canadian Intellectual Property Office (CIPO)
4. Federal Court of Canada, Rules and Practice Directions
5. Competition Bureau Canada, Intellectual Property Enforcement Guidelines
6. Patented Medicine Prices Review Board (PMPRB)
7. CanLII, Canadian Legal Information Institute